Evidence map›Paper›PMID 31138891›Full record

ArticleMolecular psychiatry2021

Variants in regulatory elements of PDE4D associate with major mental illness in the Finnish population.

Vishal Sinha, Liisa Ukkola-Vuoti, Alfredo Ortega-Alonso, Minna Torniainen-Holm, Sebastian Therman, Annamari Tuulio-Henriksson, Pekka Jylhä, Jaakko Kaprio, Iiris Hovatta, Erkki Isometsä and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. In the Brain of Phosphodiesterases: Potential Therapeutic Targets for Schizophrenia.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Protection from AmyloidThe Journal of pharmacology and experimental therapeutics · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Vishal SinhaDepartment of Public Health Solutions, Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.
Liisa Ukkola-VuotiDepartment of Public Health Solutions, Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.
Alfredo Ortega-AlonsoDepartment of Public Health Solutions, Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.
Minna Torniainen-HolmDepartment of Public Health Solutions, Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.
Sebastian ThermanDepartment of Public Health Solutions, Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.ORCID http://orcid.org/0000-0001-9407-4905
Annamari Tuulio-HenrikssonDepartment of Psychology and Logopedics, Medicum, University of Helsinki, Helsinki, Finland.
Pekka JylhäDepartment of Public Health Solutions, Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.
Jaakko KaprioInstitute for Molecular Medicine FIMM, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-3716-2455
Iiris HovattaMedicum, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-5990-7892
Erkki IsometsäDepartment of Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Tyrone D CannonDepartment of Psychology, Yale University, New Haven, Connecticut, USA.
Jouko LönnqvistDepartment of Public Health Solutions, Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.
Tiina PaunioDepartment of Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Jaana SuvisaariDepartment of Public Health Solutions, Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.ORCID http://orcid.org/0000-0001-7167-0990
William HennahDepartment of Public Health Solutions, Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland. william.hennah@helsinki.fi.
University of Helsinki · FIFinnish Institute for Health and Welfare · FIYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have previously reported a replicable association between variants at the PDE4D gene and familial schizophrenia in a Finnish cohort. In order to identify the potential functional mutations underlying these previous findings, we sequenced 1.5 Mb of the PDE4D genomic locus in 20 families (consisting of 96 individuals and 79 independent chromosomes), followed by two stages of genotyping across 6668 individuals from multiple Finnish cohorts for major mental illnesses. We identified 4570 SNPs across the PDE4D gene, with 380 associated to schizophrenia (p ≤ 0.05). Importantly, two of these variants, rs35278 and rs165940, are located at transcription factor-binding sites, and displayed replicable association in the two-stage enlargement of the familial schizophrenia cohort (combined statistics for rs35278 p = 0.0012; OR = 1.18, 95% CI: 1.06-1.32; and rs165940 p = 0.0016; OR = 1.27, 95% CI: 1.13-1.41). Further analysis using additional cohorts and endophenotypes revealed that rs165940 principally associates within the psychosis (p = 0.025, OR = 1.18, 95% CI: 1.07-1.30) and cognitive domains of major mental illnesses (g-score p = 0.044, β = -0.033). Specifically, the cognitive domains represented verbal learning and memory (p = 0.0091, β = -0.044) and verbal working memory (p = 0.0062, β = -0.036). Moreover, expression data from the GTEx database demonstrated that rs165940 significantly correlates with the mRNA expression levels of PDE4D in the cerebellum (p-value = 0.04; m-value = 0.9), demonstrating a potential functional consequence for this variant. Thus, rs165940 represents the most likely functional variant for major mental illness at the PDE4D locus in the Finnish population, increasing risk broadly to psychotic disorders.

Indexed as

Psychotic DisordersSchizophreniaCyclic Nucleotide Phosphodiesterases, Type 4EndophenotypesFinlandHumansPolymorphism, Single NucleotideCyclic Nucleotide Phosphodiesterases, Type 4PDE4D protein, human

Identifiers

PMID31138891
OpenAlexW2951220725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.